Jiangsu Recbio Advances Vaccine Development with Promising Clinical Trials

The latest announcement is out from Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ).

Jiangsu Recbio Technology Co., Ltd. announced significant advancements in its vaccine development pipeline for the year ending December 31, 2024. The company is progressing with Phase III clinical trials for its HPV 9-valent vaccine, which aims to address cervical cancer and genital warts, and is on track to submit a BLA application in 2025. Additionally, the company has completed enrollment for its shingles vaccine trial and is conducting follow-up studies to evaluate its efficacy and safety. The development of a bivalent recombinant respiratory syncytial virus vaccine is also underway, with preclinical studies expected to conclude in 2025. These developments position Jiangsu Recbio as a leading player in China’s vaccine industry, potentially impacting public health outcomes and offering new solutions for disease prevention.

More about Jiangsu Recbio Technology Co., Ltd. Class H

Jiangsu Recbio Technology Co., Ltd. is a biotechnology company based in China, focusing on the development of vaccines. The company is involved in the research and development of vaccines for diseases such as HPV, shingles, and respiratory syncytial virus, with a particular emphasis on innovative and effective vaccine solutions for the Chinese market.

YTD Price Performance: -22.21%

Average Trading Volume: 102,819

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$3.54B

Find detailed analytics on 2179 stock on TipRanks’ Stock Analysis page.